AMAG to sell MuGard in the US for Access Pharmaceuticals
Executive Summary
AMAG Pharmaceuticals Inc. (blood disorder therapy) has licensed exclusive US rights to the MuGard oral wound rinse in the US and its territories from Access Pharmaceuticals Inc. (supportive cancer care).
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice